Clinical Trials

A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer

Nanjing Chia-tai Tianqing Pharmaceutical